PURE Bioscience, Inc. (NASDAQ:
, the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that two of its distributors are featuring the PURE Hard Surface disinfectant and food contact surface sanitizer at the annual ISSA/INTERCLEAN
trade show this week in Chicago.
PURE Bioscience distributors Intercon Chemical/Clearly Better Medical in booth 2241 and Nilodor, Inc. in booth 1324 will be presenting to decision makers and buyers from several of PURE’s market channels, including facility services companies and contractor cleaners, as well as to distributors and wholesalers. ISSA/INTERCLEAN is the world’s largest trade show dedicated to cleaning products and services, attracting nearly 16,000 attendees and more than 650 exhibitors.
Michael L. Krall, President/CEO of PURE Bioscience, stated, “This year’s ISSA/INTERCLEAN conference represents a fantastic opportunity for these two distributors to continue educating the cleaning industry about the benefits of our SDC technology while increasing exposure for our cornerstone product, PURE Hard Surface. The conference theme of ’Reimagine Clean’ with its message, ’Quality cleaning is an investment, not a cost to be minimized,’ sets the stage appropriately for our distributors’ introduction of PURE Hard Surface as a responsible, next-generation disinfectant that delivers the necessary power to eliminate dangerous pathogens.”
About PURE Hard Surface
US EPA registered PURE Hard Surface disinfectant and food contact surface sanitizer provides an unparalleled combination of high efficacy and low toxicity with 30-second bacterial and viral kill times and 24-hour residual protection. PURE Hard Surface completely kills resistant pathogens like MRSA and Carbapenem-resistant
(NDM-1) and also effectively eliminates dangerous fungi and viruses including HIV, Hepatitis B, Hepatitis C, Norovirus, Influenza A, Avian Influenza and H1N1 as well as hazardous food pathogens such as
. PURE Hard Surface delivers powerful broad-spectrum efficacy while remaining classified as least-toxic (Category IV) by the US EPA, and its active ingredient, SDC, has been determined Generally Recognized as Safe (GRAS) for use as a biocide on food processing equipment, machinery and utensils.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of “green” products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s cash position and liquidity requirements, the Company’s failure to implement or otherwise achieve the benefits of its strategic initiatives, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.